T1	Condition 21 35	progressive MS
T2	Qualifier 13 20	primary
R1	Has_qualifier Arg1:T1 Arg2:T2	
T3	Procedure 62 65	MRI
T4	Mood 37 58	Inability to complete
R2	Has_mood Arg1:T3 Arg2:T4	
T5	Condition 67 84	contraindications
T6	Procedure 89 92	MRI
R3	AND Arg1:T5 Arg2:T6	
T7	Measurement 127 133	weight
T8	Value 134 141	=140 kg
R4	Has_value Arg1:T7 Arg2:T8	
T9	Device 143 152	pacemaker
T10	Device 154 171	cochlear implants
T11	Device 185 214	foreign substances in the eye
T12	Device 216 243	intracranial vascular clips
T13	Procedure 245 252	surgery
T14	Temporal 253 291	within 6 weeks of entry into the study
T15	Reference_point 271 291	entry into the study
R5	Has_index Arg1:T14 Arg2:T15	
T16	Device 293 307	coronary stent
T17	Procedure 308 317	implanted
T18	Temporal 318 370	within 8 weeks prior to the time of the intended MRI
T19	Reference_point 342 370	the time of the intended MRI
T20	Procedure 367 370	MRI
T21	Mood 358 366	intended
R6	Has_mood Arg1:T20 Arg2:T21	
R7	multi Arg1:T19 Arg2:T20	
R8	Has_index Arg1:T18 Arg2:T19	
R9	Has_temporal Arg1:T17 Arg2:T18	
R10	AND Arg1:T17 Arg2:T16	
R11	Has_temporal Arg1:T13 Arg2:T14	
*	OR T10 T9 T13 T17 T12 T11 T7
T22	Scope 127 370	weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI
T23	Scope 67 92	contraindications for MRI
R12	Subsumes Arg1:T23 Arg2:T22	
T24	Scope 67 370	contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI
T25	Scope 37 65	Inability to complete an MRI
R13	Subsumes Arg1:T25 Arg2:T22	
T26	Condition 390 401	intolerance
T27	Drug 379 389	Gadolinium
R14	AND Arg1:T26 Arg2:T27	
T28	Condition 414 448	ischemic cerebrovascular disorders
T29	Condition 456 462	stroke
T30	Condition 464 489	transient ischemic attack
*	OR T29 T30
T31	Condition 494 521	ischemia of the spinal cord
T32	Scope 456 489	stroke, transient ischemic attack
R15	Subsumes Arg1:T28 Arg2:T32	
*	OR T28 T31
T33	Condition 552 580;596 601	central nervous system (CNS) tumor
T34	Condition 584 601	spinal cord tumor
T35	Condition 609 619	meningioma
T36	Condition 621 627	glioma
*	OR T35 T36
*	OR T34 T33
T37	Scope 609 627	meningioma, glioma
T38	Scope 552 600	central nervous system (CNS) or spinal cord tumo
R16	Subsumes Arg1:T38 Arg2:T37	
T39	Condition 689 699	myelopathy
T40	Condition 669 685	metabolic causes
T41	Condition 717 739	vitamin B12 deficiency
T42	Qualifier 707 716	untreated
R18	Has_qualifier Arg1:T41 Arg2:T42	
R17	AND Arg1:T40 Arg2:T39	
T43	Scope 669 699	metabolic causes of myelopathy
T44	Scope 707 739	untreated vitamin B12 deficiency
R19	Subsumes Arg1:T43 Arg2:T44	
T45	Condition 771 788	infectious causes
T46	Condition 792 802	myelopathy
R20	AND Arg1:T45 Arg2:T46	
T47	Condition 810 818	syphilis
T48	Condition 820 832	Lyme disease
T49	Condition 834 871	human T-lymphotropic virus 1 (HTLV-1)
T50	Condition 873 897	herpes zoster myelopathy
*	OR T47 T48 T49 T50
T51	Scope 810 897	syphilis, Lyme disease, human T-lymphotropic virus 1 (HTLV-1), herpes zoster myelopathy
T52	Scope 771 802	infectious causes of myelopathy
R21	Subsumes Arg1:T52 Arg2:T51	
T53	Condition 933 970	progressive CNS degenerative disorder
T54	Qualifier 911 932	genetically inherited
R22	Has_qualifier Arg1:T53 Arg2:T54	
T55	Condition 978 1000	hereditary paraparesis
T56	Condition 1009 1031	mitochondrial myopathy
T57	Condition 1033 1047	encephalopathy
T58	Condition 1049 1064	lactic acidosis
T59	Condition 1066 1072	stroke
T60	Condition 1002 1007;1074 1082	MELAS syndrome
T61	Scope 1009 1072	mitochondrial myopathy, encephalopathy, lactic acidosis, stroke
R23	Subsumes Arg1:T60 Arg2:T61	
*	OR T55 T60
T62	Scope 978 1082	hereditary paraparesis; MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, stroke] syndrome
T63	Scope 911 970	genetically inherited progressive CNS degenerative disorder
R24	Subsumes Arg1:T63 Arg2:T62	
T64	Condition 1085 1105	Neuromyelitis optica
T65	Observation 1107 1114	History
T66	Condition 1136 1165	systemic autoimmune disorders
T67	Condition 1186 1216	progressive neurologic disease
T68	Mood 1166 1185	potentially causing
R25	Has_mood Arg1:T67 Arg2:T68	
R26	AND Arg1:T66 Arg2:T67	
T69	Condition 1224 1229	lupus
T70	Condition 1231 1266	anti-phospholipid antibody syndrome
T71	Condition 1268 1286	Sjogren's syndrome
T72	Condition 1288 1304	Behçet's disease
T73	Condition 1306 1317	sarcoidosis
*	OR T70 T69 T72 T73 T71
T74	Scope 1224 1317	lupus, anti-phospholipid antibody syndrome, Sjogren's syndrome, Behçet's disease, sarcoidosis
T75	Scope 1136 1216	systemic autoimmune disorders potentially causing progressive neurologic disease
R27	Subsumes Arg1:T75 Arg2:T74	
R28	Has_temporal Arg1:T75 Arg2:T65	
T76	Qualifier 1331 1337	severe
T77	Qualifier 1339 1361	clinically significant
T78	Condition 1371 1389	spinal cord trauma
T79	Condition 1362 1367;1383 1389	brain trauma
*	OR T78 T79
T80	Scope 1362 1389	brain or spinal cord trauma
R29	Has_qualifier Arg1:T80 Arg2:T77	
R30	Has_qualifier Arg1:T80 Arg2:T76	
T81	Condition 1397 1415	cerebral contusion
T82	Condition 1417 1440	spinal cord compression
*	OR T81 T82
T83	Scope 1397 1440	cerebral contusion, spinal cord compression
T84	Scope 1331 1389	severe, clinically significant brain or spinal cord trauma
R31	Subsumes Arg1:T84 Arg2:T83	
T85	Observation 1443 1462	Vulnerable patients
T86	Qualifier 1487 1567	Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code
R32	Has_qualifier Arg1:T85 Arg2:T86	
